TY - JOUR
T1 - Exacerbations and Decreased Lung Function Predict Nebulizer Use and Uptake in COPD and Tobacco-Exposed Persons With Preserved Spirometry
AU - for the SPIROMICS Investigators
AU - Fazio, Jane C.
AU - Hong, Andrew W.
AU - Markovic, Daniela
AU - Barr, Rgraham
AU - Bleecker, Eugene R.
AU - Bowler, Russell P.
AU - Couper, David J.
AU - Curtis, Jeffrey L.
AU - Drummond, Mbradley
AU - Fortis, Spyridon
AU - Han, Meilan K.
AU - Kim, Victor
AU - Martinez, Fernando J.
AU - Ohar, Jill
AU - Ortega, Victor E.
AU - Paine, Robert
AU - Wells, Jmichael
AU - Gandhi, Sheiphali A.
AU - Woodruff, Prescott G.
AU - Putcha, Nirupama
AU - Cooper, Christopher B.
AU - Tashkin, Donald P.
AU - Buhr, Russell G.
AU - Barjaktarevic, Igor
N1 - Publisher Copyright:
© 2026, COPD Foundation. All rights reserved.
PY - 2026/3
Y1 - 2026/3
N2 - Rationale: Nebulizers are an alternative to handheld devices for inhaled therapies in chronic obstructive pulmonary disease (COPD). Understanding nebulizer utilization patterns is essential to developing therapy guidelines. Objectives: We aimed to describe characteristics of nebulizer users versus nonusers and factors associated with baseline nebulizer use and longitudinal uptake. Methods: We analyzed the Subpopulations and Intermediate Outcome Measures in COPD Study, a prospective cohort of 2973 participants with or without tobacco use and/or COPD. We used cross-sectional multivariable logistic regression and interval-censored proportional hazard models to analyze factors associated with nebulizer use and uptake among tobacco-exposed participants with preserved spirometry (TEPS) and COPD from enrollment (Visit 1) through 4–7 years of follow-up (Visit 5). Results: Nebulizer utilization was highest in advanced COPD, 49% of Global initiative for chronic Obstructive Lung Disease (GOLD) Group D participants at baseline. Nebulizer treatments were primarily as-needed short-acting bronchodilators. Baseline nebulizer use was associated with respiratory exacerbations in the prior year (1, odds ratio [OR] 1.81, 95% confidence interval [CI] [1.24, 2.64]; 2, OR 1.86, 95% CI [1.07, 3.22]; 3 or more, OR 1.87, 95% CI [1.07, 3.28]), lower forced expiratory volume in 1 second (FEV1) (OR 2.81 per liter decrease, 95% CI [2.09, 3.77]), COPD Assessment Test (CAT) score >10 (OR 1.89, 95% CI [1.17, 3.03]), 6-minute walk distance (6MWD) (OR 1.03 per 10 meter lower 6MWD, 95% CI [1.02, 1.05]), and a history of asthma (OR 2.41, 95% CI [1.76, 3.30]). Longitudinal uptake was similarly associated with exacerbations, lower FEV1, CAT score >10, and asthma. Patterns were consistent between TEPS and COPD. Conclusion: Nebulizers were predominantly used by participants with frequent exacerbations, high symptom burden, and advanced COPD, and long-acting nebulized medications were underutilized. Randomized controlled trials are needed to compare nebulizers with hand-held devices.
AB - Rationale: Nebulizers are an alternative to handheld devices for inhaled therapies in chronic obstructive pulmonary disease (COPD). Understanding nebulizer utilization patterns is essential to developing therapy guidelines. Objectives: We aimed to describe characteristics of nebulizer users versus nonusers and factors associated with baseline nebulizer use and longitudinal uptake. Methods: We analyzed the Subpopulations and Intermediate Outcome Measures in COPD Study, a prospective cohort of 2973 participants with or without tobacco use and/or COPD. We used cross-sectional multivariable logistic regression and interval-censored proportional hazard models to analyze factors associated with nebulizer use and uptake among tobacco-exposed participants with preserved spirometry (TEPS) and COPD from enrollment (Visit 1) through 4–7 years of follow-up (Visit 5). Results: Nebulizer utilization was highest in advanced COPD, 49% of Global initiative for chronic Obstructive Lung Disease (GOLD) Group D participants at baseline. Nebulizer treatments were primarily as-needed short-acting bronchodilators. Baseline nebulizer use was associated with respiratory exacerbations in the prior year (1, odds ratio [OR] 1.81, 95% confidence interval [CI] [1.24, 2.64]; 2, OR 1.86, 95% CI [1.07, 3.22]; 3 or more, OR 1.87, 95% CI [1.07, 3.28]), lower forced expiratory volume in 1 second (FEV1) (OR 2.81 per liter decrease, 95% CI [2.09, 3.77]), COPD Assessment Test (CAT) score >10 (OR 1.89, 95% CI [1.17, 3.03]), 6-minute walk distance (6MWD) (OR 1.03 per 10 meter lower 6MWD, 95% CI [1.02, 1.05]), and a history of asthma (OR 2.41, 95% CI [1.76, 3.30]). Longitudinal uptake was similarly associated with exacerbations, lower FEV1, CAT score >10, and asthma. Patterns were consistent between TEPS and COPD. Conclusion: Nebulizers were predominantly used by participants with frequent exacerbations, high symptom burden, and advanced COPD, and long-acting nebulized medications were underutilized. Randomized controlled trials are needed to compare nebulizers with hand-held devices.
KW - COPD
KW - medication delivery systems
KW - nebulizer
KW - outcomes
KW - pulmonary physiology
UR - https://www.scopus.com/pages/publications/105034225567
UR - https://www.scopus.com/pages/publications/105034225567#tab=citedBy
U2 - 10.15326/jcopdf.2025.0714
DO - 10.15326/jcopdf.2025.0714
M3 - Article
AN - SCOPUS:105034225567
SN - 2372-952X
VL - 13
SP - 111
EP - 124
JO - Chronic Obstructive Pulmonary Diseases
JF - Chronic Obstructive Pulmonary Diseases
IS - 2
ER -